Moderate Exacerbation of COPD Group E Pulmonary TB, Newly Diagnosed Clinically in the First Month of Intensive Phase Treatment, HIV Negative
DOI:
https://doi.org/10.53366/jimki.v12i3.1018Keywords:
OPD, Pulmonary Tuberculosis, exacerbationAbstract
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disorder frequently associated with pulmonary tuberculosis (TB), particularly in individuals with risk factors such as smoking. We report a 65-year-old male with COPD group E who presented with dyspnea and chronic productive cough. The patient was diagnosed with newly detected pulmonary TB and was undergoing the intensive phase of anti-tuberculosis drug (OAT) therapy. Physical examination revealed bilateral wheezing with an oxygen saturation of 90%, which increased to 93% after administration of 2 L/min of supplemental oxygen; cardiac function was within normal limits. The patient received inhaled bronchodilators, intravenous methylprednisolone, levofloxacin, and OAT. After 10 days of hospitalization, dyspnea improved along with an increase in daily peak expiratory flow (PEF) values. This case highlights the importance of a multidisciplinary approach involving infection control and pharmacotherapy adjustment to achieve optimal clinical improvement in COPD patients with coexisting tuberculosis.
References
1. Byrne, A.L., Marais, B.J. & Mitchell, G.J. (2023) Interactions between chronic obstructive pulmonary disease and tuberculosis: current understanding and clinical implications. The Lancet Respiratory Medicine, 11(3), pp. 254–266.
2. Cresswell, F.V. et al. (2018) Implementation of drug desensitization protocols in tuberculosis treatment. Clinical Infectious Diseases, 67(6), pp. 1025–1032.
3. Cresswell, F.V. et al. (2018) Rifampicin and drug interactions in tuberculosis management. Cayman Chemical Company.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2025) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2025 Report.
5. Kementerian Kesehatan Republik Indonesia. (2023) Profil Kesehatan Indonesia 2023. Jakarta: Kemenkes RI.
6. Kim, H.Y., Lee, S.H. & Yoon, H.I. (2020) ‘Diagnostic approaches for tuberculous pleural effusion: update and perspectives,’ Tuberculosis and Respiratory Diseases, 83(3), pp. 197–206.
7. Lee, C.H. et al. (2020) ‘Impact of pulmonary tuberculosis history on chronic obstructive pulmonary disease: a population-based study,’ Respirology, 25(10), pp. 1035–1043.
8. Rabe, K.F. et al. (2023) ‘Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD 2023 Report),’ European Respiratory Journal, 61(1): 2201786.
9. Ranzani, O.T. et al. (2021) ‘Antibiotic therapy in acute exacerbation of COPD: an update on evidence and guidance,’ Chest, 160(4), pp. 1311–1323.
10. Shah, M. et al. (2022) ‘Association between COPD and active tuberculosis: a systematic review and meta-analysis,’ Chest, 162(3), pp. 621–632.
11. Wedzicha, J.A. & Seemungal, T.A.R. (2022) COPD exacerbations: mechanisms, prevention, and management. The Lancet, 400(10360), pp. 681–697.
12. World Health Organization. (2023) Treatment of Tuberculosis: Guidelines for National Programmes. 5th ed. Geneva: WHO.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Syazili Mustofa, Aisyah Ramadhani, Giska Tri Putri, Hendri Busman, Jordy Oktobiannobel
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.